WA-T-MOBILE
9.5.2022 15:21:09 CEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Battle Motors has selected the Un-carrier as the preferred provider of IoT connectivity and management for thousands of new Battle Motors battery electric trucks rolling off the Ohio-based production line. And these trucks are getting smarter, thanks to Battle Motors' all new factory installed RevolutionOS™ EV software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005589/en/
Like consumer automotive, the commercial truck industry is moving swiftly to embrace EV technology — and Battle Motors is no exception. Their RevolutionOS™, powered by T-Mobile's nationwide network, delivers actionable data and information to drivers and fleet managers that they can use to enhance efficiency, safety, and security. As part of this long-term agreement, T-Mobile for Business will deliver 4G LTE connectivity to Battle Motors trucks for near real-time sharing of battery range and usage information, historic and near real-time location and trip data, timely preventative maintenance warnings, over-the-air software, and firmware updates — as well as the truck's full bill of materials, such as VIN-specific information, parts, and manuals.
Every new Battle Motors class seven and class eight "heavy-duty" EV truck — like the ones that haul garbage, dirt, and freight — will come with a factory installed, ruggedized digital instrument cluster that runs RevolutionOS™. And thanks to the power and reliability of T-Mobile's nationwide network, Battle Motors’ RevolutionOS™ will let customers view and update critical information directly from the truck, or remotely from a desktop computer or mobile device, just by scanning a QR code!
Additionally, T-Mobile Control Center will give Battle Motors the ability to view and manage the connectivity of their trucks. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Battle Motors can easily accelerate deployment of their growing line of trucks. Battle Motors will have near real-time visibility to all their commercial trucks with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
In the near future, Battle Motors expects to leverage the Un-carrier's 5G network to meet industrial-sized challenges for years to come as their trucks’ capabilities advance and the demands on connectivity increase. T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new electric vehicle applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
“Our primary focus has been on driving technology and innovation that gives our customers value and peace-of-mind when it comes to maintenance, efficiency, safety and compliance,” says Battle Motors CSO, Paul Marsolan. “Together with T-Mobile, we’re able to merge analytics and operations to put rich, real-time decision-making data to work for our customers.”
“While we continue to grow our business market share, it energizes us to work with forward thinking companies that demonstrate leadership in areas like sustainable commercial transportation,” said Callie Field, President, T-Mobile Business Group. “Reliable connectivity, management and support is central to Battle Motors’ mission, and we’re honored that they entrusted their trucks and their customers to T-Mobile for Business.”
For more information about IoT from T-Mobile for Business, visit www.t-mobile.com/business/solutions/iot .
To find out more about Battle Motors, go to www.battlemotors.com .
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com .
About Battle Motors
Battle Motors, a leader in the development of electric vehicle (EV) technology, acquired commercial vehicle Original Equipment Manufacturer (OEM), Crane Carrier Company, LLC (CCC) in 2021. Battle Motors is the leader in the vocational truck industry, providing work-ready diesel, clean natural gas (CNG), and now EV chassis designed and manufactured in North America for the refuse and recycling markets. Battle Motor’s durable, dependable trucks are built to excel in a multitude of applications that now include middle-mile and last-mile delivery. CCC has been manufacturing commercial vehicles for 75 years and is based in New Philadelphia, Ohio. For more information please visit: https://www.battlemotors.com and follow us @BattleMotors
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom